Several studies showed PD-1/PD-L1 inhibitors with therapeutic potential in ovarian cancer.[19,20] A phase IB trial (KEYNOTE-028) included 26 patients with PD-L1-positive ovarian cancer has shown promising outcomes. This evidence concerns the gene CD274 and ovarian carcinoma.